secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alamar Biosciences, Inc. (ALMR)
CIK:        0002104204
Form:       8-K
Filed at:   2026-08-10T20:10:17+00:00
Accession:  0001193125-26-342378
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alamar Q2 revenue $29.4M (+82% YoY); guides FY26 to $116-120M
-------------------------------------------------------------

- Q2 revenue $29.4M, up 82% from $16.2M YoY; consumables +147% to $15.5M, instruments +35% to $7.8M.
- Gross margin improved to 60% vs 53% YoY; operating loss widened to $13.5M from $7.9M.
- Net loss $13.2M vs $7.0M YoY; cash and investments $256.3M at June 30, 2026.
- FY2026 revenue guidance raised to $116-120M, ~59% growth at midpoint vs 2025.
- Launched eMTBR-tau blood assay and NULISAseq Immune 340 Panel; expanded Alzheimer's partnership with Gates Ventures.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/0001193125-26-342378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2104204/000119312526342378/ck0002104204-20260810.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer